Q-omics provides the consensus-scored UBE2Q2P2 profile across patient tissues and cancer cell-line models. UBE2Q2P2 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, UBE2Q2P2 is differentially expressed in 11, with the highest sampling consensus in THCA. Additionally, UBE2Q2P2 RNA expression shows 20,086 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KICH, THCA, and THYM as cancer lineages where UBE2Q2P2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for UBE2Q2P2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes UBE2Q2P2 survival associations across molecular data types. UBE2Q2P2 RNA expression shows survival associations in the most cancer types (23). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible UBE2Q2P2 RNA expression–survival associations across cancer types. High UBE2Q2P2 expression shows unfavorable associations in KICH, THCA and LIHC, but favorable associations in STAD, READ and SKCM. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify KICH as the clearest survival context for UBE2Q2P2 RNA expression.
This table summarizes UBE2Q2P2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for UBE2Q2P2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. UBE2Q2P2 shows lower tumor expression in THCA and higher tumor expression in COAD, LIHC, LUSC, BLCA and CHOL. The THCA box plot shows higher UBE2Q2P2 RNA expression in normal versus tumor tissue (log2 FC = −0.616, t-test p < 0.001).
This table shows molecular features associated with UBE2Q2P2 in patient tissues and cancer cell lines. In patient samples, UBE2Q2P2 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
